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Abstract
Background: The study was undertaken to assess the efficacy of methotrexate (MTX) monotherapy on the
radiographic progression of individual rheumatoid arthritis (RA) patients, each of whom had received MTX
monotherapy for 3 years with an option to change to biological disease-modifying anti-rheumatic drugs
(bDMARDs). We also looked for predictors of radiographic non-progression in these patients.
Methods: Rheumatoid patients (n = 161) were prospectively followed for 3 years while receiving low-dose MTX
monotherapy unless disease was otherwise active and/or adverse events appeared. Their disease activity and
radiographic progression were evaluated with reference to disease activity score 28 (DAS28), modified health
assessment of questionnaire (mHAQ) and other indices. The change in van der Heijde-modified total Sharp score
per year (ΔTSS) was assessed using probability plots, in which the patients were classified into the subgroups
showing structural remission (REM; ΔTSS ≤0.5), radiographic progression (ΔTSS >3) or rapid radiographic progression
(RRP; ΔTSS >5).
Results: MTX monotherapy, continued until disease became active and/or adverse event appeared, was associated
with a significant improvement (p <0.0001) in the DAS28-ESR (3) scores, % DAS28 remission, and mHAQ scores
each year, from baseline to 3 years. The mHAQ remission rate (ΔmHAQ <0.5) and Boolean remission were also
improved from 16 to 60 % and 0.8 to 24.0 %, respectively. We found that the ratio of patients classified as REM
increased yearly from 62/161 (38.5 %) to 69/137 (50.4 %), while those classified as ΔTSS >3 decreased from 55/161
(34.2 %) to 28/137 (20.4 %) and those in RRP decreased from 35/161 (21.7 %) to 15/137 (10.9 %). Receiver operating
characteristic (ROC) curve analyses showed that serum matrix metalloproteinase-3 (MMP-3) <103.7 ng/ml at outset
predicts a patient subgroup that exhibits no radiographic progression.
Conclusions: Half of rheumatoid patients treated with MTX monotherapy for 3 years exhibited structural remission,
and this outcome can be predicted at the outset by lower serum MMP-3.
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Background
Methotrexate (MTX) has been recommended not only
as a first-line drug for the initial treatment of rheuma-
toid arthritis (RA), but also as an essential component of
combination therapies utilizing either conventional
disease-modifying anti-rheumatic drugs (cDMARDs) or
biological DMARDs (bDMARDs) [1, 2]. Recent studies
have shown that patients treated with a combination
therapy of MTX and bDMARDs fare better than those
given MTX alone [3–18]. However, some individual
patients have been shown to respond well to MTX mono-
therapy, i.e., they exhibit no radiographic progression.
Recently, O’Dell et al. have shown that treating patients
with MTX monotherapy initially, while later providing an
option to step up to combination therapy produces out-
comes similar to those seen with combination therapies
consisting of cDMARDS and/or bDMARDs that are pro-
vided from the outset [19]. In their study, approximately
30 % of the patients treated by MTX monotherapy did not
require subsequent combination therapy. However, this
Table 1 Profile of patients at baseline
Patients, number 161
Male/female, number 40/121
Age, years 57.4 ± 12.2 (median 58) n = 161
Onset age, years 53.0 ± 12.4 (median 54) n = 161
Disease duration, years 4.4 ± 6.9 (median 1.4) n = 161
Methotrexate used, number of patients (%) 161 (100) n = 161
Baseline methotrexate dose, mg/wk 4.3 ± 0.9 (median 4) n = 161
Prednisolone used, number (%) 38 (23.6) n = 38
Baseline prednisolone dose, mg/day 5.0 ± 3.2 n = 38
Baseline prednisolone dose, mg/day 1.2 ± 2.6 (median 0) n = 161
Conventional disease-modifying anti-rheumatic drugs used, number of patients (%) 73 (45.3) n = 161
Stage 1 73 45.3 %
Stage 2 42 26.1 %
Stage 3 28 17.4 %
Stage 4 18 11.2 %
Class I 78 48.4 %
Class II 76 47.2 %
Class III 7 4.3 %
Class IV 0 0.0 %
C-reactive protein, mg/dl 2.6 ± 3.0 (median 1.5) n = 161
Erythrocyte sedimentation rate, mm/h 55.1 ± 35.1 (median 48) n = 161
Tender joint count 7.1 ± 5.7 (median 6) n = 161
Swollen joint count 7.5 ± 5.4 (median 7) n = 161
Disease activity score in 28 joints-C-reactive protein (4) 4.8 ± 1.1 (median 4.6) n = 129
Disease activity score in 28 joints-erythrocyte sedimentation rate (4) 5.5 ± 1.2 (median 5.5) n = 129
Disease activity score in 28 joints-C-reactive protein (3) 4.5 ± 1.0 (median 4.3) n = 161
Disease activity score in 28 joints-erythrocyte sedimentation rate (3) 5.2 ± 1.1 (median 5.2) n = 161
Visual analog scale, mm 52.4 ± 28.0 (median 51) n = 129
Matrix metalloproteinase-3, ng/ml 241.9 ± 304.2 (median 133) n = 157
Rheumatoid factor 119.2 ± 226.5 (median 45.3) n = 157
Morning stiffness, minutes 165.6 ± 362.6 (median 35) n = 158
Grip strength, (L+ R)/2 mmHg 176.8 ± 66.7 (median 171) n = 157
Modified health assessment questionnaire 0.543 ± 0.469 (median 0.500) n = 130
Baseline van der Heijde modified total Sharp score 18.6 ± 33.2 (median 4.0) n = 161
Baseline van der Heijde modified total Sharp score, progression, –1 to 0 years 7.9 ± 19.0 (median 3.0) n = 161
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subgroup was reported to be clinically and radiographic-
ally indistinguishable from those who required it.
For MTX monotherapy to be more effectively employed
as a first-line drug to halt radiographic progression. it
would be useful at outset to ascertain which patients
would benefit most from MTX monotherapy and which
would require combination therapy including biologic
agents. The purpose of the present study was to assess the
efficacy of low-dose MTX monotherapy, a regimen that is
commonly prescribed in Japan, and to potentially identify
a subgroup of patients on MTX monotherapy, without
radiographic evidence of disease progression. In the
present study, 161 patients with rheumatoid arthritis were
followed unless disease was otherwise active or significant
adverse events appeared. Disease progression was scored
as the change in the modified total Sharp score per year
(ΔTSS), starting at baseline and continuing for 3 years. Pa-
tients were classified into subgroups exhibiting structural
remission (REM; ΔTSS ≤0.5), radiographic evidence of
progression (ΔTSS >3) or radiographic evidence of rapid
progression (RRP; ΔTSS >5) [20].
Methods
Patients and the study design
Patients were included who had RA (n = 161) as deter-
mined by the 1987 American College of Rheumatology
(ACR) criteria [21] and who had started MTX mono-
therapy for the first time between January 2005 and
August 2010 (Table 1). Patient consent was in accord-
ance with protocols approved by the respective institu-
tional ethical committees of Kohnan Hospital (protocol
H16.11.9) and Kyushu University (protocol 875). Only
patients who underwent MTX monotherapy for at least
7 months were included, and they were prospectively
followed for 3 years while receiving low-dose MTX
monotherapy, unless disease was otherwise active and/or
adverse events appeared. The dose of MTX used was
allowed to vary according to disease activity. Patients
who had already been receiving low-dose prednisolone
(mean 5, median 5, range 2–10) per day were included
and allowed to continue this dosing (Table 1),
whereas patients who were just starting prednisolone
were excluded. Exclusion criteria were disease activity
score in 28 joints-erythrocyte sedimentation rate (DAS28-
ESR) >4.2 and clinical disease activity index (CDAI) >22,
and/or the emergence of a significant adverse event: in
these cases, additional therapies, including bDMARDs,
were initiated. Patients were also assessed using the 2010
ACR/European League Against Rheumatism (EULAR)
criteria [22].
Assessment
Disease activity was evaluated by joint counts, visual
analog scale (VAS), morning stiffness, grip strength, C-
reactive protein (CRP), erythrocyte sedimentation rate
(ESR), rheumatoid factor (RF), matrix metalloproteinase-
3 (MMP-3), anti-citrullinated protein antibody (ACPA),
disease activity score in 28 joints (DAS28), and the
modified health assessment questionnaire (mHAQ). Pa-
tients were followed prospectively for 3 years until cessa-
tion of MTX monotherapy. Incomplete data from
patients who had dropped out because of our exclusion
criteria (n = 25) were assessed in two ways: (1) clinical
endpoints were imputed as the last observation carried
forward (LOCF) and (2) clinical endpoints were assessed
as observed. We obtained similar results with both
methods. We also followed the sequelae of patients who
had dropped out, and observations that were applicable
were described in the results. Radiographic evidence of
progression was assessed in the hands and wrists and
scored chronologically as recommended by Bruynesteyn
et al. [23] using the TSS as previously described [24].
The change in TSS per year was evaluated from the
baseline and annual evaluation of patients, and recorded
as the TSS year-progression (ΔTSS). From these data,
patients were classified into three groups: those with
structural remission (REM) (ΔTSS ≤0.5), those with
radiographic evidence of progression (ΔTSS >3), and
those with radiographic evidence of rapid progression
(RRP) (ΔTSS >5) [22]. Baseline and annual data were
assessed in relation to radiographic evidence of progres-
sion to identify a factor that could predict which sub-
group of patients may respond to treatment, i.e., patients
who showed no radiographic evidence of progression,
Table 2 Annual changes in disease activity indices and serum MMP-3 levels
0 year 1 year 2 years 3 years Number of patients
DAS28-ESR(4) 5.5 ± 1.2 4.1 ± 1.3*** 3.8 ± 1.3*** 3.6 ± 1.4*** 129
DAS28-CRP(4) 4.8 ± 1.1 3.4 ± 1.2*** 3.1 ± 1.2*** 2.6 ± 1.3*** 129
DAS28-ESR(3) 5.2 ± 1.1 4.2 ± 1.3*** 4.0 ± 1.23*** 3.9 ± 1.4*** 161
DAS28-CRP(3) 4.5 ± 1.0 3.5 ± 1.2*** 3.2 ± 1.2*** 3.1 ± 1.3*** 161
mHAQ 0.541 ± 0.470 0.269 ± 0.388*** 0.205 ± 0.318*** 0.180 ± 0.323*** 129
MMP3, ng/ml 241.9 ± 304.2 178.5 ± 287.8** 174.7 ± 299.5*** 181.5 ± 321.2*** 157
**p = 0.0015, ***p <0.0001 vs 0 year analyzed by the Wilcoxon signed-rank test. DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate,
CRP C-reactive protein, mHAQ modified health assessment questionnaire, MMP matrix metalloproteinase-3
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and did not fall into either the ΔTSS >3 or RRP
(ΔTSS >5) classification.
Statistical analysis
Radiographic evidence of progression and functional
outcomes over time were compared using the Wilcoxon
signed-rank test. Demographic and baseline characteris-
tics were analyzed using Fisher’s exact test for categor-
ical variables and the Wilcoxon rank sum test for
continuous variables. Receiver operating characteristics
(ROC) curve analysis was conducted using MMP-3 pro-
tein levels, which had been identified as a potential pre-
dictor of disease, using univariate and multivariate
analysis to determine the cutoff value for a diagnostic
test of joint damage. Multivariate analysis was performed
using multiple regression models with variables for
which the p values were <0.2 in the preceding
univariate analysis. All reported p values are two-sided
and not adjusted for multiple testing. Any difference
with a p value <0.05 was considered statistically signifi-
cant. All analyses were performed using Statview for
Windows V.5.0 (SAS Institute, Cary, NC, USA), R ver-
sion 2.15.2, and the Epi library.
Results
Effect of low-dose MTX monotherapy on disease activity
All patients who were included fulfilled the 2010 ACR/
EULAR criteria [24] and exhibited high disease activity
(mean ± SD for DAS28-ESR (3), 5.2 ± 1.1; for CRP, 2.6 ±
3.0 mg/dL) and progressive joint destruction (mean ± SD
for baseline TSS, 18.6 ± 33.2; for baseline ΔTSS for –1 to
0 years, 7.9 ± 19.0) at the time of initiation of MTX
monotherapy (Table 1). Low doses of MTX were used in
this study (mean ± SD, median: 4.3 ± 0.9 mg/wk, 4 mg/wk
Fig. 1 Annual changes in disease activity score in 28 joints (DAS28)-C-reactive protein (CRP), European League Against Rheumatism (EULAR)
response, modified health assessment questionnaire (mHAQ) and Boolean remission rate
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at baseline; 6.7 ± 2.5 mg/wk, 6 mg/wk after 1 year; 7.0 ±
2.7 mg/wk, 6 mg/wk after 2 years; 6.8 ± 2.7 mg/wk,
6 mg/wk after 3 years). Prednisolone was prescribed to 38
of 161 patients (23.6 %), with a mean ± SD dose of 5.0 ±
3.2 mg/day at baseline, 4.2 ± 2.4 mg/day after 1 year, 3.7 ±
2.0 mg/day after 2 years, and 3.5 ± 2.1 mg/day after 3 years,
respectively.
Patients with rheumatoid arthritis (n = 161) were pro-
spectively followed for 3 years while receiving low-dose
MTX monotherapy unless disease was otherwise active
and/or adverse events appeared. Disease activity was
found to be significantly improved each year starting at
baseline and continuing to 3 years: DAS28-ESR (3) de-
creased from 5.2 ± 1.1 to 3.9 ± 1.4 (p <0.0001) and DAS28-
CRP (3) from 4.5 ± 1.0 to 3.1 ± 1.3 (p <0.0001) (Table 2).
The percent DAS28-ESR (3) remission increased from 1
to 19 % (Additional file 1: Figure S1), and the percent
DAS28-CRP (3) remission increased from 4 to 39 %
(Fig. 1). The EULAR responses were also improved.
The mHAQ improved from 0.54 ± 0.47 to 0.18 ± 0.32
(p <0.0001) (Table 2), and the mHAQ remission rate
(ΔmHAQ <0.5) from 16 to 60 % (Fig. 1). The ratio of
patients who achieved Boolean remission also in-
creased from 0.8 to 24.0 % during this 3-year period
(Fig. 1). Similar results were obtained when data were
analyzed as observed instead of by the LOCF (data
not shown).
Effect of low-dose MTX monotherapy on radiographic
evidence of progression
Radiographic evidence of progression as determined by
mean ΔTSS significantly decreased over the 3-year study
period. Respective measurements (mean ± SD (n), me-
dian, statistical significance) were as follows: ΔTSS 0–1
year, 3.3 ± 5.1 (n = 161), 1.0, p <0.0001; ΔTSS 1–2 years,
2.7 ± 5.2 (n = 145), 1.0, p <0.0001; and ΔTSS 2–3 years,
2.2 ± 4.4 (n = 137), 0.5, p <0.0001. Cumulative probability
plots showed that after 1 year of MTX monotherapy, 62/
161 of the patients (38.5 %) were classified into the REM
category, 55/161 (34.2 %) into ΔTSS >3, and 35/161
(21.7 %) into RRP (Fig. 2, upper). Among the 62 patients
in the REM category, 2 (3.2 %) were clinically stable and
moved to another hospital: subsequent follow up showed
that these patients had inactive disease for the remaining
2 years. One other patient (1.6 %) with clinically active
disease had MTX monotherapy stopped and infliximab
(IFX) therapy initiated because the patient had a
DAS28-ESR (3) >3.2. Among the 20 patients in the
ΔTSS >3 but not RRP category, 3 patients (15.0 %) had
active disease and thus IFX therapy was added. Two pa-
tients (10.0 %) were stable and moved to another hos-
pital: subsequent follow up showed that they had
inactive disease for the remaining 2 years. Among the 35
patients in the RRP category, 8 patients (22.9 %) had
active disease and biologic agents were added to their
regimen. One of these patients developed mandibular
myelitis and MTX therapy was stopped for 4 months
and then resumed.
During the second year of MTX monotherapy (years
1–2), 60/145 patients (41.4 %) were classified as REM,
37/145 (25.5 %) as ΔTSS >3, and 23/145 (15.9 %) as RRP
(Fig. 2, middle). Among the 60 patients classified as
REM, one patient (0.017 %) showed signs of liver injury
and thus MTX therapy was stopped and tocilizumab
Fig. 2 Cumulative probability plots for the change in van der Heijde
modified total Sharp score per year (ΔTSS). Patient subgroups
corresponding to structural remission (REM), radiographic evidence
of progression (ΔTSS >3), or radiographic evidence of rapid
progression (RRP) are indicated. Bio indicates a patient who began
new treatment with a biologic agent. Ch indicates a patient who
moved to another hospital because of inactive disease but
continued methotrexate (MTX) treatment. Inf indicates a patient who
developed infection, mandibular myelitis, and thus discontinued
MTX treatment. Liv indicates a patient who had abnormal liver tests
and thus discontinued MTX treatment. IP indicates a patient who
developed interstitial pneumonitis and thus discontinued MTX
treatment. St indicates a patient who developed stomatitis and thus
discontinued MTX treatment
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(TCZ) was initiated. IFX was initiated in one other patient
(0.017 %) due to the patient’s personal preference, al-
though the disease was inactive. Among the 14 patients
classified as ΔTSS >3 but not RRP, disease became clinic-
ally active in one patient (7.1 %) and thus biologic agents
were added. Another patient (with ΔTSS ≤3) developed
interstitial pneumonitis and thus MTX was stopped and
tacrolimus was initiated. Among the 23 patients with RRP,
disease became clinically active in 3 (11.3 %) and thus bio-
logic agents were added. One other patient (0.04 %) devel-
oped stomatitis and thus MTX therapy was stopped.
During the third year of MTX monotherapy (years 2–3),
69/137 patients (50.4 %) were classified as REM, 28/137
(20.4 %) as ΔTSS >3, and 15/137 (10.9 %) as RRP (Fig. 2,
lower). These data indicate that over time, patients with
active disease who required biologic agents were mostly in
the RRP group, followed by the ΔTSS >3 group. This was
not the case, however, when the patients were classified
according to disease activity, i.e., DAS28 (Additional file 1:
Table S1).
In summary, during the 3 years of MTX monotherapy,
the percentage of patients classified into the REM group
increased from 38.5 to 50.4 % (p = 0.0466), those in
ΔTSS >3 decreased from 34.2 to 20.4 % (p = 0.0095), and
those in RRP decreased from 21.7 to 10.9 % (p = 0.0190)
(Fig. 2).
Search for a factor that predicts which patients will show
no radiographic evidence of progression with MTX
monotherapy
We searched for a factor that might identify a subgroup
of patients who did not have radiographic evidence of
progression as assessed by ROC curve analysis. We
found that patients with serum MMP-3 levels
<103.7 ng/ml at baseline came to be classified in neither
the ΔTSS >3 nor the RRP groups, with negative predict-
ive values (NPV) of 88.7 and 96.8 %, respectively (Fig. 3).
This cutoff level of 103.7 ng/ml was valid when male
and female patients were studied separately, with an
NPV of 88.1 % for ΔTSS >3 and 87.8 % for RRP,
Fig. 3 Receiver operating characteristics curve analysis of a radiographic evidence of progression (van der Heijde modified total Sharp score
year-progression (ΔTSS) >3)) and b radiographic evidence of rapid progression (RRP), showing that serum matrix metalloproteinase-3 (MMP-3)
levels measured at the outset of methotrexate monotherapy can predict radiographic evidence of non-progression of disease. AUC area under
the curve
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respectively (Additional file 1: Figure S2). We also noted
that as the clinical course of therapy proceeded, lower
serum MMP-3 levels predicted a subgroup that exhib-
ited no radiographic evidence of progression: 98.0 ng/ml
as measured after 1 year of MTX monotherapy with an
NPV of 86.8 % for this 1–2 year period, and 68.8 ng/ml
after 2 years of MTX monotherapy, with NPV of 93.2 %
for the 2–3 year period (Fig. 4).
Discussion
Initial application of MTX monotherapy followed by
combination therapy with bDMARDs, if necessary, is a
reasonable therapeutic strategy for treating patients with
early RA [25]. In the present study, we found that a sub-
stantial proportion of patients with RA fared well with
just MTX monotherapy: they did not exhibit radio-
graphic evidence of progression and did not require
combination therapy. This result was in part due to the
careful monitoring of patients and to the availability of
other treatment options to individuals who exhibited ac-
tive disease and/or adverse events. Nevertheless, it was
somewhat surprising to find that approximately half of
the patients who would have been considered to have a
poor prognosis as assessed by the EULAR/ACR criteria
[22] nevertheless had no radiographic evidence of pro-
gression for 3 years while being treated only with low-
dose MTX monotherapy. The dose of MTX used was
significantly lower than those used in other countries,
due to national healthcare regulations unique to Japan at
that time [26]. We considered the possibility that genetic
factors unique to the Japanese population might underlie
the high efficacy of this low-dose MTX monotherapy.
However, our findings are consistent with those of
O’Dell et al. [19] who reported that approximately 30 %
of Caucasian patients fared well with MTX monotherapy
and did not require combination therapy. The patients
in our studies may be more typical of the patients en-
countered by clinicians in daily practice compared to
those in the O’Dell study, as most patients had a signifi-
cantly longer history of disease prior to entering the
study (average 4.4 years). Many of these patients had
previous exposure to other therapies including sulfasala-
zine (36 %) or bucillamine (38 %). Our observations may
more closely represent the outcomes to be expected with
low-dose MTX monotherapy in a typical real-life patient
population, and indicates that MTX monotherapy may
Fig. 4 Receiver operating characteristics curve analysis of radiographic progression (van der Heijde modified total Sharp score year-progression
(ΔTSS) >3 versus ΔTSS ≤3, showing that serum matrix metalloproteinase-3 (MMP-3) levels of serum MMP-3 as measured at 1 year (a) or 2 years
(b) after the start of methotrexate monotherapy can predict final radiographic evidence of non-progression of disease. AUC area under the curve
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be useful as a first-line drug to halt radiographic evi-
dence of progression in RA.
As to which patients might benefit most from MTX
monotherapy and which would require additional ther-
apy with biologic agents or others to halt progression as
seen on radiography, we found that low serum MMP-3
measured at the outset of MTX monotherapy, was a
good predictor of radiographic non-progression. We fur-
ther noted that lower serum MMP-3 measured during
the course of MTX monotherapy is also a good pre-
dictor. The results are in line with the finding of Ma
et al., who found that continuously elevated serum
MMP-3 predicts radiographic evidence of progression
for 1 year in the patients treated with various cDMARDs
in a treat-to-target (T2T) protocol [27]. Previous studies
have shown that joint destruction is halted if all of the
joint-destroying MMPs including MMP-3, MMP-9 and
MMP-13 are normalized [28, 29]. Although serum
MMP-3 levels alone are a crude reflection of disease
progression [30], they presumably reflect the levels of
other joint-destroying MMPs as well, as for example
shown in the collagen-induced arthritis model in mice
[31]. These may explain why serum MMP-3, as deter-
mined by ROC curve analysis, is negatively correlated
with later radiographic evidence of progression in the
present study.
We also noted that clinically active disease emerged pri-
marily in patients in the RRP group. Patients classified as
REM or ΔTSS ≤3 seldom developed clinically active disease
during the course of MTX monotherapy, and this was es-
pecially true among patients who remained in REM for
more than 1 year of MTX monotherapy. These results sup-
port the rationale for the use of MTX monotherapy as a
first choice to halt radiographic evidence of progression,
unless or until disease becomes active and/or adverse
events appear. This rationale is further supported by recent
studies that suggest that MTX may even extend the life ex-
pectancy of patients with rheumatoid disease [32, 33].
Conclusions
In conclusion, we found that structural remission and
radiographic evidence of non-progression were respect-
ively induced in 50.4 and 79.6 % of patients with
rheumatoid disease treated continuously with MTX
monotherapy, with an option to change to bDMARDs
for 3 years. We also found that low serum MMP-3 mea-
sured at the outset of MTX monotherapy can be a good
predictor of radiographic evidence of non-progression.
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